Abivax SA Stock Drops 3.4% Amid Earnings Miss and Management Change
What happened
Abivax SA Sponsored ADR stock price declined 3.4% during mid-day trading on September 22, 2026, trading as low as $97.68. The company reported a net loss of ($1.71) earnings per share for the quarter, missing consensus estimates of ($0.92) by ($0.79). Revenue reached $1.37 million, exceeding analyst estimates of $0.80 million.
From themarketsdaily.com
Why it matters
The company announced plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026. Abivax also reported cash reserves of €402.4 million as of June 30, which, combined with recent offerings, extends the cash runway into the fourth quarter of 2029. The company appointed Tim Kelly as chief technical officer to support manufacturing and quality.
From themarketsdaily.com
Who's involved
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Incyte stock is trading on the Nasdaq exchange, with its performance being discussed in a bullish light due to strong fundamentals and earnings momentum.
- VERAXA Biotech AG listed on the Nasdaq stock exchange and appointed Carl von Halem as Interim Chief Financial Officer.
- Incannex Healthcare Inc. stock was traded on the Nasdaq exchange on June 29, 2026.
- Arrive AI traded on the Nasdaq stock exchange, with its performance covered by financial blog MarketBeat.
- Garrett Motion Inc. stock traded on the Nasdaq exchange and required filings with the SEC on September 4, 2026.